C83.79 Burkitt lymphoma, extranodal and solid organ sites

Name of the Condition

• Burkitt lymphoma, extranodal and solid organ sites
• Medical term: Burkitt's lymphoma

Summary

Burkitt lymphoma is a highly aggressive form of non-Hodgkin lymphoma that primarily affects B-cells in the lymphatic system. This subtype involves tumors located outside the lymph nodes, such as in organs or other tissues. It is characterized by rapid tumor growth and is often associated with specific genetic and viral factors. Early diagnosis and treatment are critical due to its fast progression.

Causes

The exact causes of Burkitt lymphoma are not fully understood, but it is strongly linked to infection with the Epstein-Barr virus (EBV). Genetic mutations, particularly chromosomal translocations involving the MYC gene, are also key contributors to its development.

Risk Factors

• Epstein-Barr virus (EBV) infection
• Human immunodeficiency virus (HIV) infection
• Weakened immune system from other conditions or treatments
• Young age, especially in children and young adults
• Geographic regions with high EBV prevalence, such as equatorial Africa

Symptoms

• Rapidly growing, painless masses in extranodal or solid organ sites (e.g., abdomen, kidneys, or other tissues)
• Abdominal pain or swelling (if lymphoma affects abdominal organs)
• Fever
• Night sweats
• Unexplained weight loss
• Fatigue
• Organ-specific symptoms (e.g., urinary issues if kidneys are involved)

Diagnosis

Diagnosis involves a physical examination to assess masses or organ swelling, followed by imaging tests (e.g., CT or MRI) to identify tumor locations. A biopsy of affected tissue is performed to confirm the presence of cancerous cells and determine the subtype. Laboratory tests, including blood work and genetic analysis, may also be used to support the diagnosis.

Treatment Options

Treatment typically involves intensive chemotherapy regimens, often including combinations of drugs like cyclophosphamide, vincristine, and methotrexate. For localized disease, radiation therapy may be used. In some cases, targeted therapies or immunotherapy may be considered. Treatment plans are tailored to the patient's age, overall health, and disease extent.

Prognosis and Follow-Up

With prompt and appropriate treatment, the prognosis for Burkitt lymphoma can be favorable, especially in younger patients. However, the aggressive nature of the disease requires close monitoring. Follow-up care includes regular imaging, blood tests, and clinical evaluations to detect recurrence or complications. Long-term survivors may require ongoing surveillance for late effects of treatment.

Complications

• Tumor lysis syndrome (due to rapid cell breakdown during treatment)
• Organ dysfunction (if lymphoma affects vital organs)
• Infections (from weakened immune system)
• Neurological issues (if the central nervous system is involved)
• Long-term effects from chemotherapy or radiation

Lifestyle & Prevention

• Maintain a healthy immune system through balanced nutrition and regular medical care.
• Practice safe behaviors to reduce infection risk (e.g., avoiding exposure to EBV where possible).
• Follow recommended screening for high-risk individuals (e.g., those with HIV).
• Stay informed about symptoms and seek prompt medical attention for unexplained masses or organ-related issues.

When to Seek Professional Help

Seek immediate medical care if you experience:

• Rapidly growing, painless masses in any part of the body.
• Persistent abdominal pain, swelling, or urinary symptoms.
• Unexplained fever, night sweats, or significant weight loss.
• Fatigue that interferes with daily activities.

Tips for Medical Coders

When coding for Burkitt lymphoma involving extranodal or solid organ sites, ensure the documentation specifies the affected location (e.g., abdomen, kidney, or other tissue). Verify that the diagnosis aligns with the clinical findings and that the code C83.79 is used only when the site is clearly documented as extranodal or solid organ. Accurate site documentation is critical for proper coding and reporting.